McKesson Corporation ($MCK) Stock Forecast: Up 11.0% Today

What is McKesson Corporation?

McKesson (MCK) is a healthcare company that provides pharmaceuticals and medical supplies. The company operates in the U.S. and internationally, serving healthcare providers and pharmacies.

Why is McKesson Corporation going up?

MCK stock is up 11.0% on Nov 7, 2024 20:51

• Today, McKesson's strong bullish movement is supported by several factors:
• Increased options activity and positive investor sentiment suggest confidence in the company's future.
• Second-quarter fiscal 2025 results surpassing expectations, especially in the U.S. Pharmaceutical segment, have contributed to a favorable market outlook.
• Analysts revising their forecasts upward and expressing optimism about McKesson post-earnings have further encouraged investor confidence.
• In conclusion, robust earnings performance and a positive outlook for McKesson have driven the stock's bullish trend today.

MCK Price Chart

MCK Technical Analysis

MCK News

Spotlight on McKesson: Analyzing the Surge in Options Activity - McKesson ( NYSE:MCK )

Investors with a lot of money to spend have taken a bullish stance on McKesson MCK. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

https://www.benzinga.com/insights/options/24/11/41815679/spotlight-on-mckesson-analyzing-the-surge-in-options-activity

MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up

McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.

https://www.zacks.com/stock/news/2366602/mck-stock-gains-as-q2-earnings-sales-top-estimates-25-eps-view-up

These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings - McKesson ( NYSE:MCK )

McKesson MCK reported better-than-expected second-quarter financial results on Wednesday. McKesson reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 per share. The company reported quarterly sales of $93.70 billion which beat the analyst consensus ...

https://www.benzinga.com/news/earnings/24/11/41808298/these-analysts-boost-their-forecasts-on-mckesson-following-upbeat-earnings

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - McKesson ( NYSE:MCK )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

https://www.benzinga.com/news/24/11/41804810/this-mckesson-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday

McKesson ( MCK ) Q2 Earnings and Revenues Beat Estimates

McKesson (MCK) delivered earnings and revenue surprises of 2.61% and 4.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2365556/mckesson-mck-q2-earnings-and-revenues-beat-estimates

Trending Today

Euro ($EUR/USD) Forex Forecast: Down 1.5% Today

Ethereum ($ETH) Crypto Forecast: Up 7.5% Today

Solana ($SOL) Crypto Forecast: Up 7.2% Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Up 5.1% Today

XRP ($XRP) Crypto Forecast: Up 23.5% Today

Pepe ($PEPE) Crypto Forecast: Up 9.8% Today

Cardano ($ADA) Crypto Forecast: Up 11.2% Today

Stellar ($XLM) Crypto Forecast: Up 16.7% Today

Avalanche ($AVAX) Crypto Forecast: Up 5.7% Today

Starknet ($STRK) Crypto Forecast: Up 11.6% Today

McKesson Corporation Price History

05.08.2024 - MCK Stock was down 8.3%

• The bearish movement in McKesson's stock today could be attributed to the recent $300 million opioid settlement that the company, along with other drug distributors, has agreed to pay to resolve claims from health insurers and benefit plans. This settlement could have negative financial implications for McKesson in the short term.
• Bearish options activity observed by investors on McKesson's stock further indicates a lack of confidence or pessimistic sentiment surrounding the company's future performance.
• The market may be reacting to the uncertainty and potential financial impact of the settlement on McKesson's profitability and reputation, leading to a sell-off of the stock by investors anticipating a downturn in the company's prospects.
• Overall, the combination of the negative news regarding the opioid settlement and the bearish options activity likely contributed to the significant bearish movement in McKesson's stock today.

05.08.2024 - MCK Stock was down 6.2%

• McKesson and other leading drug distributors recently reached a substantial $300 million settlement with health insurers and benefit plans related to the opioid epidemic.
• The news of the opioid settlement likely impacted investor sentiment and contributed to the drop in McKesson's stock price.
• Investors are showing apprehension regarding the financial implications of the settlement on McKesson's future profits and possible regulatory implications within the pharmaceutical distribution sector.
• The market response suggests that investors are considering the legal and financial risks associated with McKesson's involvement in the opioid crisis, leading to the downward movement in the stock.

24.08.2024 - MCK Stock was down 6.5%

• McKesson's stock decreased by -0.68% today, going against the overall market direction.
• Despite increased options activity suggesting optimism among investors, the stock did not perform positively.
• Despite strong collaborations and Biologics strength, external market conditions could have impacted the stock's decline.
• Analyst downgrades and general market sentiment likely played a role in the stock's bearish movement.

15.09.2024 - MCK Stock was up 2.3%

• Over the past 5 years, McKesson (MCK) has delivered an impressive average annual return of 29.57%, surpassing market performance by a considerable margin.
• The closing price of McKesson (MCK) stood at $502.12, reflecting a +1.42% change compared to the previous trading session.
• The robust bullish trend in McKesson's stock today may be linked to its consistent market outperformance, signaling investor trust in the company's growth prospects and financial health.

07.10.2024 - MCK Stock was up 12.4%

• Recent positive developments contributed to McKesson's stock rise:
• Increased options activity indicated investor optimism about the company's future.
• Analysts raised their forecasts post a favorable earnings report, emphasizing the company's strong financial results.
• McKesson exceeded Q2 earnings and revenue expectations, further boosting investor confidence.
• The company's long-term market outperformance, demonstrated by a significant return on investment spanning two decades, attracted more investors, leading to a rise in stock value.

07.10.2024 - MCK Stock was up 9.4%

• McKesson reported better-than-expected second-quarter financial results, with earnings of $7.07 per share and sales of $93.70 billion, beating analyst estimates. This positive earnings report likely contributed to the bullish movement.
• Analysts have turned bullish on McKesson, with upgrades and increased price targets following the upbeat earnings report. This positive sentiment from analysts could have further boosted the stock.
• The company's consistent outperformance over the past 20 years, with an average annual return of 15.46%, has likely attracted investors looking for long-term growth opportunities.
• Expectations for solid performance in the U.S. Pharmaceutical and Specialty Solutions segment in the upcoming earnings report may have also fueled investor optimism and contributed to the bullish movement in the stock.

07.10.2024 - MCK Stock was up 11.0%

• Today, McKesson's strong bullish movement is supported by several factors:
• Increased options activity and positive investor sentiment suggest confidence in the company's future.
• Second-quarter fiscal 2025 results surpassing expectations, especially in the U.S. Pharmaceutical segment, have contributed to a favorable market outlook.
• Analysts revising their forecasts upward and expressing optimism about McKesson post-earnings have further encouraged investor confidence.
• In conclusion, robust earnings performance and a positive outlook for McKesson have driven the stock's bullish trend today.

27.05.2024 - MCK Stock was down 1.9%

• McKesson's stock closed at $599.56 today, experiencing a -0.8% change from the previous day.
• Uncertainty among investors following the announcement of McKesson Corporation's first quarter fiscal 2025 earnings release date possibly contributed to the stock's bearish movement.
• Despite the healthcare sector's positive outlook, reflected in the Health Care Select Sector SPDR Fund's 7% YTD gain, various company-specific or market factors may have influenced McKesson's stock decline.
• Investor optimism regarding McKesson's Biologics business could serve as a catalyst for a potential stock recovery in the near term.

11.06.2024 - MCK Stock was down 2.0%

• Investor profit-taking after recent stock gains could have driven the bearish trend in McKesson.
• An analyst increasing the price target for MCK may have heightened expectations, prompting some investors to sell and secure profits.
• The general market shift towards dividend stocks might have influenced trading activity, causing some investors to move away from MCK in search of different investment opportunities.
• Developments like insider selling at Qualcomm and adjustments in price targets for stocks such as NVIDIA and Robinhood may have influenced market sentiment, playing a role in the negative movement of MCK.

08.07.2024 - MCK Stock was down 8.5%

• Weak sales in the first quarter resulted in a significant drop in McKesson's stock price.
• Despite falling short on core earnings, McKesson's stock target was raised by Mizuho, signaling some positivity about the company's future prospects.
• The underperformance in quarterly revenue was primarily linked to the U.S. pharmaceutical segment, with specialty drugs sales acting as a major drag on overall sales.
• While Q1 earnings exceeded expectations, the stock price decline today is likely a response to concerns about poor sales and revenue misses in the U.S. pharmaceutical segment.

08.07.2024 - MCK Stock was down 12.1%

• Supply and demand issues for weight-loss drugs led to a bearish movement for McKesson, impacting service sales negatively.
• Analysts' expectations were not met as the company's revenue forecast for the year fell short, resulting in a decline in stock price.
• Despite weak sales and core earnings miss, McKesson saw its stock target raised by Mizuho, hinting at optimism for the company's future performance.
• McKesson's bearish market movement today was influenced by supply chain challenges, a revenue forecast miss, and mixed analyst sentiment.

08.07.2024 - MCK Stock was down 12.5%

• The company witnessed a significant decline in its stock price today following weaker than anticipated first-quarter sales results.
• McKesson (MCK) outperformed earnings expectations and displayed revenue growth in the U.S. Pharmaceutical segment. However, reduced COVID-related sales adversely affected overall performance, particularly in the Medical Surgical Solutions segment.
• Despite falling short of core earnings expectations, a stock target increase by Mizuho could suggest some positive outlook for the company's future.
• The lower-than-expected quarterly revenue, especially in the U.S. pharmaceutical segment, where specialty drug sales for complex conditions declined, likely influenced the negative market trend.